数字与计算病理学在肾细胞癌中的临床应用:系统综述
本系统综述检索截至2022年12月的英文文献,纳入20项回顾性研究,评估数字与计算病理学在肾细胞癌检测、肿瘤特征描述和患者结局方面的应用。研究表明该技术潜力巨大且初步结果有前景,但尚无研究全面评估临床效用与实施,模型尚未达到可整合进常规临床实践的水平。
要点
- 纳入20项回顾性研究,所有数字病理技术均为回顾性实施。
- 研究按主要目标分为检测、肿瘤特征描述和患者结局三类。
- 多个研究显示有前景的潜力,但尚无研究全面评估临床效用与实施。
核心结论
- 数字与计算病理学在肾细胞癌的检测、分类和肿瘤学结局评估方面具有巨大潜力,初步工作已取得有前景的结果,但这些模型尚未达到可整合进常规临床实践的水平。
研究设计与样本
- 系统综述,遵循PRISMA指南,检索PubMed、Web of Science和Scopus数据库(2022年12月),PROSPERO注册号CRD42023389282,最终纳入20篇文章。
- 所有纳入研究均采用回顾性设计,所有数字病理技术均为回顾性实施。
- 偏倚风险按预测模型研究偏倚风险评估工具(PROBAST)评估。
主要发现
- 纳入的20项研究按主要目标分为检测、肿瘤特征描述和患者结局三类。
- 在向临床实践转化方面,多个研究显示出有前景的潜力,但无研究全面评估临床效用与实施。
- 模型构建策略和报告的性能指标均存在显著异质性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 所有纳入研究均为回顾性设计,所有数字病理技术均为回顾性实施。
- 无研究全面评估临床效用与实施。
- 模型构建策略和报告的性能指标均存在显著异质性。
- 这些模型尚未达到可整合进常规临床实践的水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Computational pathology is a new interdisciplinary field that combines traditional pathology with modern technologies such as digital imaging and machine learning to better understand the diagnosis, prognosis, and natural history of many diseases. OBJECTIVE: To provide an overview of digital and computational pathology and its current and potential applications in renal cell carcinoma (RCC). EVIDENCE ACQUISITION: A systematic review of the English-language literature was conducted using the PubMed, Web of Science, and Scopus databases in December 2022 according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines (PROSPERO ID: CRD42023389282). Risk of bias was assessed according to the Prediction Model Study Risk of Bias Assessment Tool. EVIDENCE SYNTHESIS: In total, 20 articles were included in the review. All the studies used a retrospective design, and all digital pathology techniques were implemented retrospectively. The studies were classified according to their primary objective: detection, tumor characterization, and patient outcome. Regarding the transition to clinical practice, several studies showed promising potential. However, none presented a comprehensive assessment of clinical utility and implementation. Notably, there was substantial heterogeneity for both the strategies used for model building and the performance metrics reported. CONCLUSIONS: This review highlights the vast potential of digital and computational pathology for the detection, classification, and assessment of oncological outcomes in RCC. Preliminary work in this field has yielded promising results. However, these models have not yet reached a stage where they can be integrated into routine clinical practice. PATIENT SUMMARY: Computational pathology combines traditional pathology and technologies such as digital imaging and artificial intelligence to improve diagnosis of disease and identify prognostic factors and new biomarkers. The number of studies exploring its potential in kidney cancer is rapidly increasing. However, despite the surge in research activity, computational pathology is not yet ready for widespread routine use.
引用
- Khene ZE, Kammerer-Jacquet SF, Bigot P, et al. Clinical Application of Digital and Computational Pathology in Renal Cell Carcinoma: A Systematic Review. Eur Urol Oncol. 2023. PMID: 37925349. doi:10.1016/j.euo.2023.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。